Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4761986
Max Phase: Preclinical
Molecular Formula: C66H94F2N10O10
Molecular Weight: 1225.53
Molecule Type: Unknown
Associated Items:
ID: ALA4761986
Max Phase: Preclinical
Molecular Formula: C66H94F2N10O10
Molecular Weight: 1225.53
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
Standard InChI: InChI=1S/C66H94F2N10O10/c1-41(2)62-75-74-42(3)78(62)50-34-48-18-19-49(35-50)77(48)31-24-51(73-63(84)45-21-25-64(67,68)26-22-45)44-13-16-47(17-14-44)71-57(82)39-86-37-55(80)69-29-9-7-5-4-6-8-10-30-70-56(81)38-87-40-58(83)72-52-23-27-66(85)54-33-46-15-20-53(79)60-59(46)65(66,61(52)88-60)28-32-76(54)36-43-11-12-43/h13-17,20,41,43,45,48-52,54,61,79,85H,4-12,18-19,21-40H2,1-3H3,(H,69,80)(H,70,81)(H,71,82)(H,72,83)(H,73,84)/t48-,49+,50+,51-,52+,54+,61-,65-,66+/m0/s1
Standard InChI Key: LRWWYYRQZRJLHU-KMUKYJBTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1225.53 | Molecular Weight (Monoisotopic): 1224.7122 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Arnatt CK,Falls BA,Yuan Y,Raborg TJ,Masvekar RR,El-Hage N,Selley DE,Nicola AV,Knapp PE,Hauser KF,Zhang Y. (2016) Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization., 24 (22.0): [PMID:27720326] [10.1016/j.bmc.2016.09.059] |
Source(1):